Results 161 to 170 of about 1,123,091 (301)

Combining clinical chemistry with metabolomics for metabolic phenotyping at population levels. [PDF]

Metabolomics
Xu Y, Wilson ID, Goodacre R.
europepmc   +1 more source

The Togo national proficiency test pilot programme for basic clinical chemistry tests. [PDF]

Afr J Lab Med, 2022
Kouassi KC, Dorkenoo AM, Gbada K, Afanyibo YG, Têko M, Koura A.   +5 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Hematological and clinical-chemistry parameters of kratom users: a comparative study of users and non-users in Southern Thailand. [PDF]

Sci Rep
La-Up A, Saengow U, Aramrattana A.
europepmc   +1 more source

Lot verification practices in Ontario clinical chemistry laboratories - Results of a patterns-of-practice survey. [PDF]

Pract Lab Med, 2022
Rutledge AC, Johnston A, Booth RA, Veljkovic K, Bailey D, Vandenberghe H, Waite G, Allen LC, Don-Wauchope A, Chan PC, Stemp J, Edmond P, Leung V, Aslan B.   +13 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Insights and prospects for ion mobility-mass spectrometry in clinical chemistry. [PDF]

Expert Rev Proteomics, 2022
Koomen DC, May JC, McLean JA.
europepmc   +1 more source

Toxicology, Clinical Chemistry [PDF]

, 2004
佐久間 勉, 宮原 龍郎, 根本 信雄   +2 more
core   +3 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Early Post-Transplant Protein Biomarkers for Risk Stratification of Renal Allograft Dysfunction: Diagnostic Value and Clinical Chemistry Perspectives. [PDF]

Diseases
Bot Rachisan AL, Aldea PL, Bulata B, Delean D, Elec F, Sparchez M.   +5 more
europepmc   +1 more source